The Australia & New Zealand research antibodies market size is expected to reach USD 186.6 million by 2026 according to a new report by Grand View Research, Inc., exhibiting a CAGR of 8.4%. Drivers of this market include rise in R&D initiatives being undertaken by biopharmaceutical & biotechnology companies, increase in government investments on R&D, and growth in neurobiology & stem cell research.
Rise in R&D investments and research activities by various pharmaceutical and biotechnology companies to develop new & innovative products is anticipated to fuel market growth. For instance, in March 2019, the Federal Government invested USD 150 million in Stem Cells Australia and University of Melbourne to support R&D pertaining to stem cell and explore new ways to treat various life-threatening conditions such as stroke, congenital heart disease, and kidney disease.
Growth in stem cell and neurobiology-based research is expected to boost the market during the forecast period. There are a number of neurobiology-based research institutes in Australia. For instance, the Center of Research Excellence in Neuromuscular Disorders, Australia, is a collaboration between neuromuscular experts.
Request a Sample Copy of the Australia & New Zealand Research Antibodies Market Research Report @ www.grandviewresearch.com/industry-analysis/australia-new-zealand-research-antibodies-market
Ongoing launch of new products is anticipated to fuel market growth over the forecast period. For instance, in April 2019, Bio-Rad launched a range of isotype-specific secondary antibodies-IgG1, IgG2a, and IgG2b. These products are used for specificity in ELISA, imaging, western blotting, and flow cytometry as well as to improve signaling.
Increasing adoption of strategies, such as collaborations and acquisitions, by leading market players is expected to fuel market growth. For instance, in March 2016, Thermo Fisher Scientific Inc., announced the acquisition of Affymetrix, Inc. This strategic acquisition was aimed at strengthening the company’s position in the field of bioscience and expanding its portfolio of antibodies.
New Zealand has been investing heavily in R&D in order to promote trade in biotechnology sector. According to Research, Science and Innovation System Performance Report, the nation’s total expenditure on R&D was estimated to be 1.23% of GDP in 2016. This was funded by both public and private firms in New Zealand. Data from the same source also indicates that the country’s science system is highly productive in terms of publications per researcher, with over USD 653,400 spent on research and higher education.
Further key findings from the study suggest:
- Primary antibodies held dominant share of the product segment in 2018. This can be attributed to wide applications of these antibodies in research
- Monoclonal antibodies held significant share of the type segment in 2018, mainly due to their efficient staining properties and high specificity for detection of antigens
- Western blotting held the largest share of the technology segment owing to rising demand for rapid diagnostic methods
- On the basis of technology, ELISA is anticipated to witness the highest CAGR during the forecast period, owing to conventional use of polyclonal antibodies for sandwich ELISA
- On the basis of source, mouse segment held the largest share of the Australia & New Zealand research antibodies market in 2018, as mice are convenient to use during production of antibodies for research purposes.
Have Any Query? Ask Our Experts @ www.grandviewresearch.com/inquiry/6528/ibb
Grand View Research has segmented the Australia & New Zealand research antibodies market report on the basis of product, type, technology, source, application, end use, and country:
Australia & New Zealand Research Antibodies Product Outlook (Revenue, USD Million, 2015 – 2026)
Australia & New Zealand Research Antibodies Type Outlook (Revenue, USD Million, 2015 – 2026)
- Monoclonal Antibodies
- Polyclonal Antibodies
Australia & New Zealand Research Antibodies Technology Outlook (Revenue, USD Million, 2015 – 2026)
- Western Blotting
- Flow Cytometry
Australia & New Zealand Research Antibodies Source Outlook (Revenue, USD Million, 2015 – 2026)
Australia & New Zealand Research Antibodies Application Outlook (Revenue, USD Million, 2015 – 2026)
- Infectious Diseases
- Stem Cells
Australia & New Zealand Research Antibodies End-use Outlook (Revenue, USD Million, 2015 – 2026)
- Academic & Research Institutes
- Contract Research Organizations
- Pharmaceutical & Biotechnology Companies
Australia & New Zealand Research Antibodies Regional Outlook (Revenue, USD Million, 2015 – 2026)
- New Zealand
Browse Related Report:
Liquid Biopsy Market: www.grandviewresearch.com/industry-analysis/liquid-biopsy-market
Protein Labeling Market: www.grandviewresearch.com/industry-analysis/protein-labeling-market
About Grand View Research
Grand View Research provides syndicated as well as customized research reports and consulting services on 46 industries across 25 major countries worldwide. This U.S.-based market research and consulting company is registered in California and headquartered in San Francisco. Comprising over 425 analysts and consultants, the company adds 1200+ market research reports to its extensive database each year. Supported by an interactive market intelligence platform, the team at Grand View Research guides Fortune 500 companies and prominent academic institutes in comprehending the global and regional business environment and carefully identifying future opportunities.
Company Name: Grand View Research, Inc.
Contact Person: Sherry James, Corporate Sales Specialist – U.S.A.
Email: Send Email
Phone: 1-415-349-0058, Toll Free: 1-888-202-9519
Address:201, Spear Street, 1100
City: San Francisco
Country: United States